10th European Congress on Tropical Medicine and International Health
October 16-20, 2017

Antwerp, Belgium

The main objective of ECTMIH 2017 was to provide a platform for state-of-the-art updates and recent breakthroughs in the field of tropical medicine and global health.

DNDi presented on sleeping sickness, visceral leishmaniasis, mycetoma, and onchocerciasis.


Download DNDi@ECTMIH flyer


Phase II/III results for fexinidazole, the first oral treatment for human African trypanosomiasis (HAT)

Date: Tuesday, October 17, 2017

Organizer: Nathalie Strub Wourgaft, Medical Director, DNDi

José Ramon Franco, WHO
Developing treatments for sleeping sickness: DNDi’s R&D strategy
Nathalie Strub Wourgaft, Medical Director, DNDi
Results from the pivotal trial of fexinidazole: non-inferiority shown to the gold standard NECT
Antoine Tarral, Head of HAT Clinical Program, DNDi
The efficacy of fexinidazole in children and stage 1 patients
Clélia Bardonneau, Senior Clinical Project Manager HAT, DNDi

Film – ‘The Last Mile’

Structured discussion 1: Working together across continents to organize and run clinical trials in remote areas
Wilfried Mutombo Kalonji, Project Coordinator HAT, DNDi
Olaf Valverde Mordt, Medical Manager HAT, DNDi

Structured discussion 2: The potential impact of fexinidazole on the global strategy to eliminate sleeping sickness
Crispin Lumbala, Director, PNLTHA RDC
Pere Perez Simarro, HAT Access Advisor, DNDi


Oral Presentations

Hepatitis C care in resource-contained settings – do we have a scalable public health approach anno 2017?

Date: Wednesday, October 18, 2017

The innovative R&D model of the Drug for Neglected Diseases initiative (DNDi) to increase access to HCV care in low- and middle-income countries
Andrieux-Meyer, I


Kala-azar elimination in the Indian subcontinent

Date: Thursday, October 19, 2017

Phlebotomus argentipes Sand Fly control in Bangladesh: A cluster randomized controlled trial
Chowdhury R, Faria S, Huda MM, Chowdhury V, Mondal D, Akhter S, Akter S, Nabi SG, Kroeger A, Argaw D, Alvar J


International Partnerships and Collaboration

Date: Thursday, October 19, 2017

Building a visceral leishmaniasis data-sharing platform to optimize treatment and inform future research
Guerin PJ, Otieno M, Alvar J, on behalf of the IDDO VL data platform


Poster Sessions

Date: Tuesday, October 17, 2017

Clinical mentoring via mobile teams – a new approach to visceral leishmaniasis care in resource constrained settings in Africa
den Boer M, Herrero M, Lado M, Atiaby A, Ochol D, Adera C, Alvar J, Mekonen B, Ritmeijer K

Screening the pathogen box and the stasis box to identify compounds inhibiting Madurella mycetomatis growth in vitro and in vivo
Lim W, Konings M, Melse Y, Todd M, Perry B, Ioset JR, van de Sande W


Date: Wednesday, October 18, 2017

The Human African Trypanosomiasis (HAT) Platform / Plateforme Trypanosomiase Humaine Africaine (THA)
Mbo F, Valverde O

Is long lasting insecticide treated bed net able to reduce visceral leishmaniasis incidence? The evidence in Bangladesh
Chowdhury R, Chowdhury V, Faria S, Dash AP, Bhattacharya SK, Akter S, Akhter S, Argaw D, Bern C, Alvar J, Banu Q

Projected number of people with onchocerciasis-loiasis co-infection in Africa, 1995-2025
Vinkeles Melchers NVS, Tekle AH, Coffeng LE, Pion SDS, Zouré HGM, Pedrique B, Boussinesq M, Wanji S, Remme JHF, Stolk WA

Thursday, October 19, 2017

Visceral leishmaniasis treatment access – The reality on the ground in Sudan
Atiaby A, Alkhatim SS, Elhag MS, Herrero M, Paintain L, Webster J, Alvar J, Ritmeijer K, den Boer M



More information: